Colorectal cancer statistics, 2020

CA Cancer Journal for Clinicians

Volumn 70, Issue 3, 2020, Pages 145-164

  Siegel, Rebecca L ^a   Miller, Kimberly D ^a   Goding Sauer, Ann ^a   Fedewa, Stacey A ^a   Butterly, Lynn F ^b,c   Anderson, Joseph C ^c,d   Cercek, Andrea ^e   Smith, Robert A ^a   Jemal, Ahmedin ^a  

^a AMERICAN CANCER SOCIETY   (United States)

^b DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^c DARTMOUTH MEDICAL SCHOOL   (United States)

^d VA MEDICAL CENTER   (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

colon and rectum neoplasms; epidemiology; health disparities; screening and early detection

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER MORTALITY; CANCER SCREENING; CANCER STATISTICS; CANCER SURVIVAL; CHILD; COLORECTAL CANCER; CONTROLLED STUDY; EARLY CANCER DIAGNOSIS; ETHNICITY; FEMALE; HEALTH CARE ACCESS; HEALTH DISPARITY; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NEWBORN; PREVALENCE; PRIORITY JOURNAL; UNITED STATES; CANCER REGISTRY; CLINICAL TRIAL; COLORECTAL TUMOR; INCIDENCE; MULTICENTER STUDY; STATISTICAL MODEL; SURVIVAL RATE;

AGED; COLORECTAL NEOPLASMS; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MODELS, STATISTICAL; SEER PROGRAM; SURVIVAL RATE; UNITED STATES;

EID: 85082331167     PISSN: 00079235     EISSN: 15424863     Source Type: Journal    
DOI: 10.3322/caac.21601     Document Type: Article

References (107)

1. Islami F, Goding Sauer A, Miller KD, et al. Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States. CA Cancer J Clin. 2018;68:31-54.
2. Winawer SJ, Zauber AG. The advanced adenoma as the primary target of screening. Gastrointest Endosc Clin N Am. 2002;12:1-9, v.
3. Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: North American Association of Central Cancer Registries (NAACCR) Incidence–CiNA Analytic File, 1995-2016, for NHIAv2 Origin, Custom File With County, ACS Facts and Figures projection Project. North American Association of Central Cancer Registries; 2019.
4. Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Incidence-SEER 9 Regs Research Data With Delay Adjustment, Nov. 2018 Sub (1975-2016) -Linked To County Attributes-Total US, 1969-2017 Counties. National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program, Surveillance Systems Branch; 2019.
5. Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Incidence-SEER 18 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases, Nov. 2018 Sub (2000-2016)-Linked To County Attributes-Total US, 1969-2017 Counties. National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program, Surveillance Systems Branch; 2019.
6. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2016. National Cancer Institute; 2019.
7. Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Mortality-All COD, Aggregated With State, Total US (1969-2017) . National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program, Cancer Statistics Branch; 2019; underlying mortality data provided by National Center for Health Statistics, 2019.
8. Wingo PA, Cardinez CJ, Landis SH, et al. Long-term trends in cancer mortality in the United States, 1930-1998. Cancer. 2003;97(suppl 12):3133-3275.
9. Centers for Disease Control and Prevention. Behavioral Risk Factor Surveillance System Survey Data. Accessed September 4, 2019. cdc.gov/brfss/
10. Centers for Disease Control and Prevention. Methodologic changes in the Behavioral Risk Factor Surveillance System in 2011 and potential effects on prevalence estimates. MMWR Morb Mortal Wkly Rep. 2012;61:410-413.
11. National Center for Health Statistics, Division of Health Interview Statistics. National Health Interview Survey Public Use Data File 2018. Centers for Disease Control and Prevention; 2019.
12. Chen HS, Portier K, Ghosh K, et al. Predicting US- and state-level cancer counts for the current calendar year: part I: evaluation of temporal projection methods for mortality. Cancer. 2012;118:1091-1099.
13. Zhu L, Pickle LW, Ghosh K, et al. Predicting US- and state-level cancer counts for the current calendar year: part II: evaluation of spatiotemporal projection methods for incidence. Cancer. 2012;118:1100-1109.
14. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7-34.
15. Percy C, Fritz A, Jack A, et al, eds. International Classification of Diseases for Oncology. 3rd ed. World Health Organization; 2000.
16. Yin D, Morris CR, Bates JH, German RR. Effect of misclassified underlying cause of death on survival estimates of colon and rectal cancer. J Natl Cancer Inst. 2011;103:1130-1133.
17. Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat software. Surveillance Research Program, National Cancer Institute; 2019.
18. Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: National Program of Cancer Registries (NPCR) and SEER Incidence-US Cancer Statistics (USCS) file for Delay Adjustment-1999-2016-jbk 072919. Surveillance Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute; 2019.
19. Clegg LX, Feuer EJ, Midthune DN, Fay MP, Hankey BF. Impact of reporting delay and reporting error on cancer incidence rates and trends. J Natl Cancer Inst. 2002;94:1537-1545.
20. Statistical Research and Applications Branch, National Cancer Institute. Joinpoint Regression Program. Version 4.7.0.0. Statistical Research and Applications Branch, National Cancer Institute; 2019.
21. Statistical Research and Applications Branch, National Cancer Institute. DevCan—Probability of Developing or Dying of Cancer Software. Version 6.7.7. Surveillance Research Program, Statistical Methodology and Applications, National Cancer Institute; 2019.
22. Siegel RL, Fedewa SA, Anderson WF, et al. Colorectal cancer incidence patterns in the United States, 1974-2013. J Natl Cancer Inst. 2017;109:djw322.
23. Iacopetta B. Are there two sides to colorectal cancer? Int J Cancer. 2002;101:403-408.
24. Nawa T, Kato J, Kawamoto H, et al. Differences between right- and left-sided colon cancer in patient characteristics, cancer morphology and histology. J Gastroenterol Hepatol. 2008;23:418-423.
25. Lee GH, Malietzis G, Askari A, Bernardo D, Al-Hassi HO, Clark SK. Is right-sided colon cancer different to left-sided colorectal cancer? A systematic review. Eur J Surg Oncol. 2015;41:300-308.
26. Loupakis F, Yang D, Yau L, et al. Primary tumor location as a prognostic factor in metastatic colorectal cancer. J Natl Cancer Inst. 2015;107:dju427.
27. Buron Pust A, Alison R, Blanks R, et al. Heterogeneity of colorectal cancer risk by tumour characteristics: large prospective study of UK women. Int J Cancer. 2017;140:1082-1090.
28. Schoenfeld P, Cash B, Flood A, et al. Colonoscopic screening of average-risk women for colorectal neoplasia. N Engl J Med. 2005;352:2061-2068.
29. Meissner HI, Breen N, Klabunde CN, Vernon SW. Patterns of colorectal cancer screening uptake among men and women in the United States. Cancer Epidemiol Biomarkers Prev. 2006;15:389-394.
30. Murphy G, Devesa SS, Cross AJ, Inskip PD, McGlynn KA, Cook MB. Sex disparities in colorectal cancer incidence by anatomic subsite, race and age. Int J Cancer. 2011;128:1668-1675.
31. Carethers JM, Doubeni CA. Causes of socioeconomic disparities in colorectal cancer and intervention framework and strategies. Gastroenterology. 2020;158:354-367.
32. Semega J, Kollar M, Creamer J, Mohanty A, US Census Bureau. Current Population Reports. P60-266. Income and Poverty in the United States: 2018. US Government Printing Office; 2019.
33. Doubeni CA, Laiyemo AO, Major JM, et al. Socioeconomic status and the risk of colorectal cancer: an analysis of more than a half million adults in the National Institutes of Health-AARP Diet and Health Study. Cancer. 2012;118:3636-3644.
34. Doubeni CA, Major JM, Laiyemo AO, et al. Contribution of behavioral risk factors and obesity to socioeconomic differences in colorectal cancer incidence. J Natl Cancer Inst. 2012;104:1353-1362.
35. Lansdorp-Vogelaar I, Kuntz KM, Knudsen AB, van Ballegooijen M, Zauber AG, Jemal A. Contribution of screening and survival differences to racial disparities in colorectal cancer rates. Cancer Epidemiol Biomarkers Prev. 2012;21:728-736.
36. Fedewa SA, Flanders WD, Ward KC, et al. Racial and ethnic disparities in interval colorectal cancer incidence: a population-based cohort study. Ann Intern Med. 2017;166:857-866.
37. Laiyemo AO, Doubeni C, Pinsky PF, et al. Race and colorectal cancer disparities: health-care utilization vs different cancer susceptibilities. J Natl Cancer Inst. 2010;102:538-546.
38. Sineshaw HM, Robbins AS, Jemal A. Disparities in survival improvement for metastatic colorectal cancer by race/ethnicity and age in the United States. Cancer Causes Control. 2014;25:419-423.
39. Coughlin SS, Blumenthal DS, Seay SJ, Smith SA. Toward the elimination of colorectal cancer disparities among African Americans. J Racial Ethn Health Disparities. 2016;3:555-564.
40. Sineshaw HM, Ng K, Flanders WD, Brawley OW, Jemal A. Factors that contribute to differences in survival of black vs white patients with colorectal cancer. Gastroenterology. 2018;154:906-915.e907.
41. Wallace K, Grau MV, Ahnen D, et al. The association of lifestyle and dietary factors with the risk for serrated polyps of the colorectum. Cancer Epidemiol Biomarkers Prev. 2009;18:2310-2317.
42. Torre LA, Sauer AM, Chen MS Jr, Kagawa-Singer M, Jemal A, Siegel RL. Cancer statistics for Asian Americans, Native Hawaiians, and Pacific Islanders, 2016: converging incidence in males and females. CA Cancer J Clin. 2016;66:182-202.
43. Conway AA, Gerry JM, Sacco F, Wren SM. High prevalence of adenomatous polyps in Alaska Native people aged 40-49 years. J Surg Res. 2019;243:524-530.
44. Kelly JJ, Alberts SR, Sacco F, Lanier AP. Colorectal cancer in Alaska Native people, 2005-2009. Gastrointest Cancer Res. 2012;5:149-154.
45. Perdue DG, Haverkamp D, Perkins C, Daley CM, Provost E. Geographic variation in colorectal cancer incidence and mortality, age of onset, and stage at diagnosis among American Indian and Alaska Native people, 1990-2009. Am J Public Health. 2014;104(suppl 3):S404-S414.
46. McMahon BJ, Bruce MG, Koch A, et al. The diagnosis and treatment of Helicobacter pylori infection in Arctic regions with a high prevalence of infection: expert commentary. Epidemiol Infect. 2016;144:225-233.
47. Sonnenberg A, Genta RM. Helicobacter pylori is a risk factor for colonic neoplasms. Am J Gastroenterol. 2013;108:208-215.
48. Butt J, Varga MG, Blot WJ, et al. Serologic response to Helicobacter pylori proteins associated with risk of colorectal cancer among diverse populations in the United States. Gastroenterology. 2019;156:175-186.e172.
49. Day LW, Espey DK, Madden E, Segal M, Terdiman JP. Screening prevalence and incidence of colorectal cancer among American Indian/Alaskan Natives in the Indian Health Service. Dig Dis Sci. 2011;56:2104-2113.
50. Carmichael H, Cowan M, McIntyre R, Velopulos C. Disparities in colorectal cancer mortality for rural populations in the United States: does screening matter? Am J Surg. Published online September 26, 2019. doi:10.1016/j.amjsurg.2019.09.027
51. Berkowitz Z, Zhang X, Richards TB, Nadel M, Peipins LA, Holt J. Multilevel small-area estimation of colorectal cancer screening in the United States. Cancer Epidemiol Biomarkers Prev. 2018;27:245-253.
52. Martin J, Halm EA, Tiro JA, et al. Reasons for lack of diagnostic colonoscopy after positive result on fecal immunochemical test in a safety-net health system. Am J Med. 2017;130:93.e1-93.e7.
53. Redwood D, Provost E, Perdue D, Haverkamp D, Espey D. The last frontier: innovative efforts to reduce colorectal cancer disparities among the remote Alaska Native population. Gastrointest Endosc. 2012;75:474-480.
54. Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global patterns and trends in colorectal cancer incidence and mortality. Gut. 2017;66:683-691.
55. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61:212-236.
56. Edwards BK, Ward E, Kohler BA, et al. Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer. 2010;116:544-573.
57. Harewood GC, Lieberman DA. Colonoscopy practice patterns since introduction of Medicare coverage for average-risk screening. Clin Gastroenterol Hepatol. 2004;2:72-77.
58. Phillips KA, Liang SY, Ladabaum U, et al. Trends in colonoscopy for colorectal cancer screening. Med Care. 2007;45:160-167.
59. Schenck AP, Peacock SC, Klabunde CN, Lapin P, Coan JF, Brown ML. Trends in colorectal cancer test use in the Medicare population, 1998-2005. Am J Prev Med. 2009;37:1-7.
60. Holford TR. Understanding the effects of age, period, and cohort on incidence and mortality rates. Annu Rev Public Health. 1991;12:425-457.
61. Araghi M, Soerjomataram I, Bardot A, et al. Changes in colorectal cancer incidence in seven high-income countries: a population-based study. Lancet Gastroenterol Hepatol. 2019;4:511-518.
62. Austin H, Henley SJ, King J, Richardson LC, Eheman C. Changes in colorectal cancer incidence rates in young and older adults in the United States: what does it tell us about screening. Cancer Causes Control. 2014;25:191-201.
63. Siegel RL, Torre LA, Soerjomataram I, et al. Global patterns and trends in colorectal cancer incidence in young adults. Gut. 2019;68:2179-2185.
64. Vuik FE, Nieuwenburg SA, Bardou M, et al. Increasing incidence of colorectal cancer in young adults in Europe over the last 25 years. Gut. 2019;68:1820-1826.
65. Schreuders EH, Ruco A, Rabeneck L, et al. Colorectal cancer screening: a global overview of existing programmes. Gut. 2015;64:1637-1649.
66. Doll R. Progress against cancer: an epidemiologic assessment. The 1991 John C. Cassel Memorial Lecture. Am J Epidemiol. 1991;134:675-688.
67. Ang CSP, Shen JP, Hardy-Abeloos CJ, et al. Genomic landscape of appendiceal neoplasms. JCO Precision Oncol. 2018;2:1-18.
68. McCusker ME, Cote TR, Clegg LX, Sobin LH. Primary malignant neoplasms of the appendix: a population-based study from the Surveillance, Epidemiology and End Results program, 1973-1998. Cancer. 2002;94:3307-3312.
69. Johncilla M, Stachler M, Misdraji J, et al. Mutational landscape of goblet cell carcinoids and adenocarcinoma ex goblet cell carcinoids of the appendix is distinct from typical carcinoids and colorectal adenocarcinomas. Mod Pathol. 2018;31:989-996.
70. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC Cancer Staging Manual and the future of TNM. Ann Surg Oncol. 2010;17:1471-1474.
71. American Joint Commission on Cancer. Summary of Changes: Understanding the Changes from the Sixth to the Seventh Edition of the AJCC Staging Manual. American Joint Commission on Cancer; 2010. Accessed December 30, 2019. cancerstaging.org/references-tools/deskreferences/Documents/AJCCSummaryofChanges.pdf
72. Bosman FT, Carneiro F, Hruban RH, Theise ND. WHO Classification of Tumours of the Digestive System. 4th ed. Vol 3. World Health Organization; 2010.
73. North American Association of Central Cancer Registries ICD-O-3 Update Implementation Work Group. Guidelines for ICD-O-3 Update Implementation. Effective January 1, 2019. Accessed December 31, 2019. naaccr.org/wp-content/uploads/2019/12/ICD-O-3-Implementation-Guide-FINAL.pdf
74. Marmor S, Portschy PR, Tuttle TM, Virnig BA. The rise in appendiceal cancer incidence: 2000-2009. J Gastrointest Surg. 2015;19:743-750.
75. van den Heuvel MG, Lemmens VE, Verhoeven RH, de Hingh IH. The incidence of mucinous appendiceal malignancies: a population-based study. Int J Colorectal Dis. 2013;28:1307-1310.
76. Flum DR, Koepsell T. The clinical and economic correlates of misdiagnosed appendicitis: nationwide analysis. Arch Surg. 2002;137:799-804.
77. Zauber AG. The impact of screening on colorectal cancer mortality and incidence: has it really made a difference? Dig Dis Sci. 2015;60:681-691.
78. Sauer AG, Siegel RL, Jemal A, Fedewa SA. Updated review of prevalence of major risk factors and use of screening tests for cancer in the United States. Cancer Epidemiol Biomarkers Prev. 2017;26:1192-1208.
79. Singh GK, Jemal A. Socioeconomic and racial/ethnic disparities in cancer mortality, incidence, and survival in the United States, 1950-2014: over six decades of changing patterns and widening inequalities. J Environ Public Health. 2017;2017:2819372.
80. Muthukrishnan M, Arnold LD, James AS. Patients' self-reported barriers to colon cancer screening in federally qualified health center settings. Prev Med Rep. 2019;15:100896.
81. Fedewa SA, Siegel RL, Jemal A. Are temporal trends in colonoscopy among young adults concordant with colorectal cancer incidence? J Med Screen. 2019;26:179-185.
82. Wolf AMD, Fontham ETH, Church TR, et al. Colorectal cancer screening for average-risk adults: 2018 guideline update from the American Cancer Society. CA Cancer J Clin. 2018;68:250-281.
83. Fedewa SA, Siegel RL, Goding Sauer A, Bandi P, Jemal A. Colorectal cancer screening patterns after the American Cancer Society's recommendation to initiate screening at age 45 years. Cancer. Published online December 18, 2019. doi:10.1002/cncr.32662
84. Tsai MH, Xirasagar S, Li YJ, de Groen PC. Colonoscopy screening among US adults aged 40 or older with a family history of colorectal cancer. Prev Chronic Dis. 2015;12:E80.
85. Miller KD, Nogueira L, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin. 2019;69:363-385.
86. Andrew AS, Parker S, Anderson JC, et al. Risk factors for diagnosis of colorectal cancer at a late stage: a population-based study. J Gen Intern Med. 2018;33:2100-2105.
87. Ward E, Jemal A, Cokkinides V, et al. Cancer disparities by race/ethnicity and socioeconomic status. CA Cancer J Clin. 2004;54:78-93.
88. Bach PB, Schrag D, Brawley OW, Galaznik A, Yakren S, Begg CB. Survival of blacks and whites after a cancer diagnosis. JAMA. 2002;287:2106-2113.
89. Ellis L, Canchola AJ, Spiegel D, Ladabaum U, Haile R, Gomez SL. Racial and ethnic disparities in cancer survival: the contribution of tumor, sociodemographic, institutional, and neighborhood characteristics. J Clin Oncol. 2018;36:25-33.
90. Eaglehouse YL, Georg MW, Shriver CD, Zhu K. Racial comparisons in timeliness of colon cancer treatment in an equal-access health system. J Natl Cancer Inst. Published online July 4, 2019. doi:10.1093/jnci/djz153
91. Yothers G, Sargent DJ, Wolmark N, et al. Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials. J Natl Cancer Inst. 2011;103:1498-1506.
92. Doubeni CA, Rustgi A. Racial disparities in colorectal cancer survival: is elimination of variation in care the cure? J Natl Cancer Inst. 2015;107:djv229.
93. Abraham A, Habermann EB, Rothenberger DA, et al. Adjuvant chemotherapy for stage III colon cancer in the oldest old: results beyond clinical guidelines. Cancer. 2013;119:395-403.
94. Murphy CC, Harlan LC, Lund JL, Lynch CF, Geiger AM. Patterns of colorectal cancer care in the United States: 1990-2010. J Natl Cancer Inst. 2015;107:djv198.
95. Feinstein AR, Sosin DM, Wells CK. The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. N Engl J Med. 1985;312:1604-1608.
96. Hillner BE, Siegel BA, Liu D, et al. Impact of positron emission tomography/computed tomography and positron emission tomography (PET) alone on expected management of patients with cancer: initial results from the National Oncologic PET Registry. J Clin Oncol. 2008;26:2155-2161.
97. Chu KC, Tarone RE, Chow WH, Hankey BF, Ries LAG. Temporal patterns in colorectal cancer incidence, survival, and mortality from 1950 through 1990. J Natl Cancer Inst. 1994;86:997-1006.
98. Gross CP, Andersen MS, Krumholz HM, McAvay GJ, Proctor D, Tinetti ME. Relation between Medicare screening reimbursement and stage at diagnosis for older patients with colon cancer. JAMA. 2006;296:2815-2822.
99. Lieberman DA, Weiss DG, Bond JH, Ahnen DJ,Garewal H, Chejfec G. Use of colonoscopy to screen asymptomatic adults for colorectal cancer. Veterans Affairs Cooperative Study Group 380. N Engl J Med. 2000;343:162-168.
100. Wancata LM, Banerjee M, Muenz DG, Haymart MR, Wong SL. Conditional survival in advanced colorectal cancer and surgery. J Surg Res. 2016;201:196-201.
101. Chua TC, Saxena A, Chu F, Zhao J, Morris DL. Predictors of cure after hepatic resection of colorectal liver metastases: an analysis of actual 5- and 10-year survivors. J Surg Oncol. 2011;103:796-800.
102. Zampino MG, Magni E, Ravenda PS, et al. Treatments for colorectal liver metastases: a new focus on a familiar concept. Crit Rev Oncol Hematol. 2016;108:154-163.
103. Ruers T, Van Coevorden F, Punt CJ, et al. Local treatment of unresectable colorectal liver metastases: results of a randomized phase II trial. J Natl Cancer Inst. 2017;109:djx015.
104. Kopetz S, Chang GJ, Overman MJ, et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol. 2009;27:3677-3683.
105. Piawah S, Venook AP. Targeted therapy for colorectal cancer metastases: a review of current methods of molecularly targeted therapy and the use of tumor biomarkers in the treatment of metastatic colorectal cancer. Cancer. 2019;125:4139-4147.
106. Tsilimigras DI, Ntanasis-Stathopoulos I, Bagante F, et al. Clinical significance and prognostic relevance of KRAS, BRAF, PI3K and TP53 genetic mutation analysis for resectable and unresectable colorectal liver metastases: a systematic review of the current evidence. Surg Oncol. 2018;27:280-288.
107. Margonis GA, Buettner S, Andreatos N, et al. Association of BRAF mutations with survival and recurrence in surgically treated patients with metastatic colorectal liver cancer. JAMA Surg. 2018;153:e180996.